Pain relief using implantable neurostimulation has come on a lot in recent times. For evidence, try searching our pages. Now Medtronic plc has received U.S. FDA approval for Vanta™, a high performance recharge-free implantable neurostimulator (INS) with a device life that can be optimized up to 11 years.
Background
Medtronic says it is continually innovating to advance spinal cord stimulation therapy technologies that improve quality of life for people with chronic pain. The Vanta neurostimulator represents a 10% increase in longevity compared to PrimeAdvanced™, Medtronic’s previous generation recharge-free device. It is also 20% smaller, with a more rounded, ergonomic contouring to offer enhanced comfort. The Vanta system provides access to Snapshot™ reporting, Medtronic’s proprietary data insights solution. This offers clinicians objective reporting of patient activity levels to empower objective health conversations.
Medtronic claims that at comparable settings, the Vanta neurostimulator offers nearly twice the device life of competitive primary cell devices. The device utilizes Medtronic’s proprietary AdaptiveStim™ technology for personalized pain relief. This means it adapts to the patient’s movement or body position using a built-in accelerometer. AdaptiveStim technology goes beyond in-office programming by automatically adjusting stimulation to maintain each patient’s optimal dose. The Vanta neurostimulator also provides unmatched full-body MRI access with Medtronic SureScan™ technology. Approximately 82% of SCS-implanted patients will need at least one MRI within five years of implant.
Physician comments
“Not every patient with chronic, intractable pain is an ideal candidate for a rechargeable device, so the Vanta INS represents a welcome addition to my portfolio of available treatment options,” said Krishnan Chakravarthy, M.D., Ph.D., a San Diego-based interventional pain management physician.
“The extended battery life, broad MRI compatibility and personalized relief through AdaptiveStim technology allow for a more hassle-free experience and greater freedom for my patients as we manage their chronic pain.”
Company comments
“We are committed to delivering innovative solutions that meets the needs of every patient,” said Charlie Covert, vice president and general manager, Pain Therapies within the Neuromodulation business.
“For those who prefer or require a recharge-free device, I believe the Vanta neurostimulator offers the best hardware and features available today. We are pleased to offer this solution, which is now part of the strongest and broadest overall portfolio in this market.”
Source: PR Newswire
published: June 10, 2021 in: Approval/Clearance, Medtronic, Neuro, Pain management